Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Our commentary is prompted by the recent release of information on the two most promising areas of drug development in the treatment of ovarian cancer: the vascular endothelial growth factor inhibitor bevacizumab and the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor olaparib. Firstly, positive results, chiefly in terms of progression-free survival (PFS), have now been reported for bevacizumab in both first-line and recurrent/resistant disease settings. This has led many clinicians to conclude that the agent should now be incorporated into the standard management of this disease. On the other hand, a press release in December 2011 indicated that the development of olaparib in serous ovarian cancer was in question following a review of an interim analysis of a phase II study (Study 19) . This had indicated that in a maintenance therapy trial, the previously reported PFS benefit was unlikely to translate into an overall survival (OS) benefit. This press release led to ...
- http://www.astrazeneca.com/Media/Press-releases/Article/20111220-az-updates-olaparib-TC5214-development, 2011.
- Broglio, KR, Berry, DA (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101: pp. 1642-9 CrossRef
- Stuart, GC, Kitchener, H, Bacon, M (2011) 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21: pp. 750-5 CrossRef
- Sjoquist KM, Lee C, Lord S, et al. Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC). J Clin Oncol. 2012;30. suppl; abstr 5081.
- Booth, CM, Eisenhauer, EA (2012) Progression-free survival: meaningful or simply measurable?. J Clin Oncol 30: pp. 1030-3 CrossRef
- Burger, RA, Brady, MF, Bookman, MA (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: pp. 2473-83 CrossRef
- Perren, TJ, Swart, AM, Pfisterer, J (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: pp. 2484-96 CrossRef
- Aghajanian, C, Blank, SV, Goff, BA (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30: pp. 2039-45 CrossRef
- Pujade-Lauraine E, Hilpert F, Weber B, et al: AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol (suppl; abstr LBA5002^), 2012.
- Ledermann, J, Harter, P, Gourley, C (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366: pp. 1382-92 CrossRef
- Ang JE, Gourley C, High HA, et al. Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: a multi-institutional study. J Clin Oncol. 2012;30. suppl; abstr 5022.
- Edwards, SL, Brough, R, Lord, CJ (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451: pp. 1111-1115 CrossRef
- Sridhara, R, Johnson, JR, Justice, R (2010) Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst 102: pp. 230-43 CrossRef
- Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?
Current Oncology Reports
Volume 14, Issue 6 , pp 483-485
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Ovarian cancer
- Poly(adenosine diphosphate ribose) polymerase inhibitors
- End point
- Industry Sectors